JP2007524650A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007524650A5 JP2007524650A5 JP2006526473A JP2006526473A JP2007524650A5 JP 2007524650 A5 JP2007524650 A5 JP 2007524650A5 JP 2006526473 A JP2006526473 A JP 2006526473A JP 2006526473 A JP2006526473 A JP 2006526473A JP 2007524650 A5 JP2007524650 A5 JP 2007524650A5
- Authority
- JP
- Japan
- Prior art keywords
- antitumor agent
- antitumor
- agent
- cancer
- effect
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006526473A JP4930055B2 (ja) | 2004-02-25 | 2005-02-25 | 抗腫瘍剤 |
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004050520 | 2004-02-25 | ||
| JP2004050520 | 2004-02-25 | ||
| US56607704P | 2004-04-29 | 2004-04-29 | |
| US60/566,077 | 2004-04-29 | ||
| JP2006526473A JP4930055B2 (ja) | 2004-02-25 | 2005-02-25 | 抗腫瘍剤 |
| PCT/JP2005/003689 WO2005079827A2 (en) | 2004-02-25 | 2005-02-25 | Antitumor agent |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007524650A JP2007524650A (ja) | 2007-08-30 |
| JP2007524650A5 true JP2007524650A5 (https=) | 2008-04-10 |
| JP4930055B2 JP4930055B2 (ja) | 2012-05-09 |
Family
ID=34889383
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006526473A Expired - Lifetime JP4930055B2 (ja) | 2004-02-25 | 2005-02-25 | 抗腫瘍剤 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US7951780B2 (https=) |
| EP (1) | EP1718322B1 (https=) |
| JP (1) | JP4930055B2 (https=) |
| AT (1) | ATE516041T1 (https=) |
| CA (1) | CA2557540A1 (https=) |
| CY (1) | CY1111926T1 (https=) |
| DK (1) | DK1718322T3 (https=) |
| PL (1) | PL1718322T3 (https=) |
| PT (1) | PT1718322E (https=) |
| SI (1) | SI1718322T1 (https=) |
| WO (1) | WO2005079827A2 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4238728B2 (ja) * | 2001-08-21 | 2009-03-18 | アステラス製薬株式会社 | ヒストンデアセチラーゼ阻害剤の医薬用途ならびにその抗腫瘍効果の評価方法 |
| US8673888B2 (en) * | 2002-04-05 | 2014-03-18 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Depsipeptide for therapy of kidney cancer |
| EP1595952A4 (en) * | 2003-02-19 | 2008-05-21 | Astellas Pharma Inc | METHOD FOR EVALUATING THE ANTITUMOR EFFECT OF A HISTONE DEACETYLASE INHIBITOR |
| ES2425083T3 (es) * | 2003-09-25 | 2013-10-11 | Astellas Pharma Inc. | Agente antitumoral que comprende FK228 como inhibidor de histona desacetilasa y doxorrubicina como inhibidor de topoisomerasa II |
| US7951780B2 (en) | 2004-02-25 | 2011-05-31 | Astellas Pharma Inc. | Antitumor agent |
| CA2627129A1 (en) * | 2005-11-04 | 2007-05-18 | Merck & Co., Inc. | Methods of using saha and bortezomib for treating cancer |
| US20070129290A1 (en) * | 2005-11-18 | 2007-06-07 | Or Yat S | Metabolite derivatives of the HDAC inhibitor FK228 |
| EP2012801A4 (en) * | 2006-04-24 | 2009-08-05 | Gloucester Pharmaceuticals Inc | GEMCITABINE COMBINATION THERAPY |
| US8957027B2 (en) * | 2006-06-08 | 2015-02-17 | Celgene Corporation | Deacetylase inhibitor therapy |
| DK2596801T3 (en) * | 2006-10-06 | 2018-08-13 | Bavarian Nordic As | RECOMBINANT MODIFIED VACCINIA ANKARA VIRUS CODING A HER-2 ANTIGEN FOR USING CANCER TREATMENT |
| AU2007342028B2 (en) * | 2006-12-29 | 2013-06-13 | Celgene Corporation | Purifiction of romidepsin |
| CN101687010A (zh) * | 2006-12-29 | 2010-03-31 | 格洛斯特制药公司 | 制备Romidepsin |
| WO2010036404A2 (en) * | 2008-05-09 | 2010-04-01 | University Of Maryland, Baltimore | Novel retinamide retinoic acid metabolism blocking agents |
| EP2366398A1 (en) * | 2010-03-17 | 2011-09-21 | Deutsches Krebsforschungszentrum | Cancer therapy with a parvovirus combined with an HDAC inhibitor |
| JP6031437B2 (ja) * | 2010-06-07 | 2016-11-24 | アブラクシス バイオサイエンス， エルエルシー | 増殖性疾患を処置するための組み合わせ療法 |
| NZ605526A (en) | 2010-07-12 | 2015-04-24 | Celgene Corp | Romidepsin solid forms and uses thereof |
| US8859502B2 (en) | 2010-09-13 | 2014-10-14 | Celgene Corporation | Therapy for MLL-rearranged leukemia |
| AU2013202506B2 (en) | 2012-09-07 | 2015-06-18 | Celgene Corporation | Resistance biomarkers for hdac inhibitors |
| AU2013202507B9 (en) | 2012-11-14 | 2015-08-13 | Celgene Corporation | Inhibition of drug resistant cancer cells |
| NZ630311A (en) | 2013-12-27 | 2016-03-31 | Celgene Corp | Romidepsin formulations and uses thereof |
| CN106860872B (zh) * | 2017-01-18 | 2019-03-22 | 上海交通大学 | 用于逆转肿瘤对铂类抗癌药多药耐药性的两亲性药-药纳米颗粒药物及其制备方法与应用 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8817743D0 (en) | 1988-07-26 | 1988-09-01 | Fujisawa Pharmaceutical Co | Fr901228 substance & preparation thereof |
| JPH0315810A (ja) * | 1989-06-13 | 1991-01-24 | Minolta Camera Co Ltd | カメラ |
| CA2308565A1 (en) * | 1997-11-05 | 1999-05-14 | Baylor College Of Medicine | Sequences for targeting metastatic cells |
| JP2003513912A (ja) * | 1999-11-10 | 2003-04-15 | ワーナー−ランバート・カンパニー | 組合せ化学療法 |
| CN1414971A (zh) * | 1999-12-08 | 2003-04-30 | 埃克斯西特治疗公司 | 用作免疫抑制剂的缩肽及其同类物 |
| ATE425177T1 (de) | 2000-07-17 | 2009-03-15 | Astellas Pharma Inc | Reduziertes fk228 und seine verwendung |
| WO2002020817A1 (en) | 2000-09-01 | 2002-03-14 | Fujisawa Pharmaceutical Co., Ltd. | A method of producing fr901228 |
| DK1355566T3 (da) * | 2000-12-18 | 2013-03-04 | Univ Texas | Lokal regional kemoterapi og radioterapi ved anvendelse af hydrogel in situ |
| US6905669B2 (en) * | 2001-04-24 | 2005-06-14 | Supergen, Inc. | Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase |
| US6620816B2 (en) * | 2001-04-26 | 2003-09-16 | Bristol-Myers Squibb Company | Method for treating tumors by the administration of tegafur, uracil, folinic acid, and cyclophosphamide |
| JP4238728B2 (ja) | 2001-08-21 | 2009-03-18 | アステラス製薬株式会社 | ヒストンデアセチラーゼ阻害剤の医薬用途ならびにその抗腫瘍効果の評価方法 |
| SK1102004A3 (sk) * | 2001-08-31 | 2005-05-05 | Bristol-Myers Squibb Company | Liečivo na liečenie proliferačných ochorení a farmaceutická kompozícia na liečenie rakoviny |
| EP1293205A1 (en) | 2001-09-18 | 2003-03-19 | G2M Cancer Drugs AG | Valproic acid and derivatives thereof for the combination therapy of human cancers, for the treatment of tumour metastasis and minimal residual disease |
| US8673888B2 (en) | 2002-04-05 | 2014-03-18 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Depsipeptide for therapy of kidney cancer |
| AU2003226408B2 (en) | 2002-04-15 | 2007-06-14 | Sloan-Kettering Institute For Cancer Research | Combination therapy for the treatment of cancer |
| PA8578001A1 (es) * | 2002-08-07 | 2004-05-07 | Warner Lambert Co | Combinaciones terapeuticas de inhibidores de quinasa de erb b y terapias antineoplasicas |
| WO2004064727A2 (en) | 2003-01-16 | 2004-08-05 | Georgetown University | Method of cancer treatment using hdac inhibitors |
| EP1595952A4 (en) | 2003-02-19 | 2008-05-21 | Astellas Pharma Inc | METHOD FOR EVALUATING THE ANTITUMOR EFFECT OF A HISTONE DEACETYLASE INHIBITOR |
| SI2238982T1 (sl) | 2003-06-27 | 2013-01-31 | Astellas Pharma Inc. | Terapevtsko sredstvo za mehkotkivni sarkom |
| CA2472842C (en) | 2003-07-22 | 2012-05-29 | Honda Motor Co., Ltd. | Working machine |
| ES2425083T3 (es) | 2003-09-25 | 2013-10-11 | Astellas Pharma Inc. | Agente antitumoral que comprende FK228 como inhibidor de histona desacetilasa y doxorrubicina como inhibidor de topoisomerasa II |
| US7951780B2 (en) | 2004-02-25 | 2011-05-31 | Astellas Pharma Inc. | Antitumor agent |
| US20050187148A1 (en) | 2004-02-25 | 2005-08-25 | Yoshinori Naoe | Antitumor agent |
-
2005
- 2005-02-24 US US11/064,292 patent/US7951780B2/en not_active Expired - Lifetime
- 2005-02-25 CA CA002557540A patent/CA2557540A1/en not_active Abandoned
- 2005-02-25 WO PCT/JP2005/003689 patent/WO2005079827A2/en not_active Ceased
- 2005-02-25 PT PT05719967T patent/PT1718322E/pt unknown
- 2005-02-25 DK DK05719967.1T patent/DK1718322T3/da active
- 2005-02-25 AT AT05719967T patent/ATE516041T1/de active
- 2005-02-25 PL PL05719967T patent/PL1718322T3/pl unknown
- 2005-02-25 JP JP2006526473A patent/JP4930055B2/ja not_active Expired - Lifetime
- 2005-02-25 EP EP05719967A patent/EP1718322B1/en not_active Expired - Lifetime
- 2005-02-25 SI SI200531350T patent/SI1718322T1/sl unknown
-
2011
- 2011-03-11 US US13/046,082 patent/US8822422B2/en active Active
- 2011-10-10 CY CY20111100965T patent/CY1111926T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007524650A5 (https=) | ||
| Helm et al. | Enhancing the efficacy of cisplatin in ovarian cancer treatment–could arsenic have a role | |
| JP2008528671A5 (https=) | ||
| JP2014508804A5 (https=) | ||
| Olesya et al. | Antimicrobial activity of mono-and polynuclear platinum and palladium complexes | |
| EP2481402A3 (en) | Nanoparticle comprising rapamycin and albumin as anticancer agent | |
| JP2004534850A5 (https=) | ||
| JP2013507423A5 (https=) | ||
| NO2016021I1 (no) | 5-amino-2,4,7-triokso-3,4,7,8-tetrahydro-2Hpyrido[2,3-D]pyrimidinderivater og relaterte forbindelser for behandling av kreft | |
| JP2015508103A5 (https=) | ||
| JP2009543802A5 (https=) | ||
| JP2020097577A5 (https=) | ||
| JP2009502743A5 (https=) | ||
| JP2010532768A5 (https=) | ||
| JP2006501176A5 (https=) | ||
| JP2010540556A5 (https=) | ||
| JP2005511597A5 (https=) | ||
| CA2706832A1 (en) | Mevalonic acid derivatives | |
| CN1950376A (zh) | 莪术醇衍生物、含该衍生物的组合物及所述衍生物的制药用途 | |
| JP2017533223A5 (https=) | ||
| JP2007520452A5 (https=) | ||
| JP2015502926A5 (https=) | ||
| JP2012526766A5 (https=) | ||
| RU2017141536A (ru) | Замещенные производные индол-5-ола и их терапевтические применения | |
| CN109563091A (zh) | Fgfr4抑制剂及其制备方法和应用 |